ATE345327T1 - Verfahren zur herstellung von amorphem atorvastatin kalzium - Google Patents
Verfahren zur herstellung von amorphem atorvastatin kalziumInfo
- Publication number
- ATE345327T1 ATE345327T1 AT00973115T AT00973115T ATE345327T1 AT E345327 T1 ATE345327 T1 AT E345327T1 AT 00973115 T AT00973115 T AT 00973115T AT 00973115 T AT00973115 T AT 00973115T AT E345327 T1 ATE345327 T1 AT E345327T1
- Authority
- AT
- Austria
- Prior art keywords
- atorvastatin calcium
- amorphous atorvastatin
- producing amorphous
- crude
- amorphous
- Prior art date
Links
- OJRHUICOVVSGSY-RXMQYKEDSA-N (2s)-2-chloro-3-methylbutan-1-ol Chemical compound CC(C)[C@H](Cl)CO OJRHUICOVVSGSY-RXMQYKEDSA-N 0.000 title abstract 5
- 229960001770 atorvastatin calcium Drugs 0.000 title abstract 5
- 238000004519 manufacturing process Methods 0.000 title 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 abstract 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 229960005370 atorvastatin Drugs 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000001816 cooling Methods 0.000 abstract 1
- 238000010438 heat treatment Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000003960 organic solvent Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 238000001953 recrystallisation Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pyrrole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU9903634A HU226640B1 (en) | 1999-10-18 | 1999-10-18 | Process for producing amorphous atorvastatin calcium salt |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE345327T1 true ATE345327T1 (de) | 2006-12-15 |
Family
ID=90014241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00973115T ATE345327T1 (de) | 1999-10-18 | 2000-10-17 | Verfahren zur herstellung von amorphem atorvastatin kalzium |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1235800B1 (de) |
| JP (1) | JP2003512354A (de) |
| KR (1) | KR100664353B1 (de) |
| CN (1) | CN1157374C (de) |
| AT (1) | ATE345327T1 (de) |
| AU (1) | AU1166301A (de) |
| CA (1) | CA2388018C (de) |
| CZ (1) | CZ300071B6 (de) |
| DE (1) | DE60031882T2 (de) |
| HR (1) | HRP20020334B1 (de) |
| HU (1) | HU226640B1 (de) |
| PL (1) | PL354604A1 (de) |
| RS (1) | RS50473B (de) |
| RU (1) | RU2255932C2 (de) |
| SK (1) | SK286861B6 (de) |
| UA (1) | UA72777C2 (de) |
| WO (1) | WO2001028999A1 (de) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7411075B1 (en) | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
| SI20425A (sl) * | 1999-12-10 | 2001-06-30 | LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. | Priprava amorfnega atorvastatina |
| US7501450B2 (en) | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| WO2002057229A1 (en) | 2001-01-19 | 2002-07-25 | Biocon India Limited | FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN) |
| DE10135493A1 (de) * | 2001-07-20 | 2003-01-30 | Jobst Krauskopf | Pharmazeutische Zusammensetzung zur Behandlung von Hypercholesterinämie |
| EE200400048A (et) | 2001-07-30 | 2004-04-15 | Dr. Reddy's Laboratories Ltd. | Atorvastatiinkaltsiumi kristalsed vormid VI ja VII |
| JP4308021B2 (ja) * | 2002-03-18 | 2009-08-05 | バイオコン・リミテッド | 望ましい粒子サイズのアモルファスＨＭＧ−ＣｏＡレダクターゼ阻害剤 |
| RU2309141C2 (ru) * | 2002-03-18 | 2007-10-27 | Байокон Лимитид | АМОРФНЫЕ ИНГИБИТОРЫ ГМГ-КоА-РЕДУКТАЗЫ И СПОСОБ ИХ ПОЛУЧЕНИЯ |
| ITMI20020907A1 (it) * | 2002-04-29 | 2003-10-29 | Chemi Spa | Processo di preparazione della forma amorfa del sale di calcio della atorvastatina |
| AU2002356423A1 (en) * | 2002-05-28 | 2003-12-12 | Cadila Healthcare Limited | Process for the preparation of amorphous atorvastatin calcium |
| HU227041B1 (en) * | 2003-03-24 | 2010-05-28 | Richter Gedeon Nyrt | Process for the synthesis of amorphous atorvastatin calcium |
| US7790197B2 (en) | 2003-06-09 | 2010-09-07 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
| US20050271717A1 (en) | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
| US7655692B2 (en) * | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
| CZ298382B6 (cs) * | 2004-03-10 | 2007-09-12 | Zentiva, A. S. | Zpusob prípravy amorfní formy hemivápenaté soli atorvastatinu a její stabilizace |
| CA2666359A1 (en) | 2004-03-17 | 2005-10-06 | Yatendra Kumar | Process for the production of atorvastatin calcium in amorphous form |
| AU2005232959A1 (en) * | 2004-04-16 | 2005-10-27 | Pfizer Products Inc. | Process for forming amorphous atorvastatin calcium |
| CN1692906A (zh) * | 2004-04-30 | 2005-11-09 | 鲁南制药集团股份有限公司 | 治疗高血脂症的组合物 |
| US7875731B2 (en) | 2004-05-05 | 2011-01-25 | Pfizer Inc. | Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)Carbonyl]-1H-pyrrole-1-heptanoic acid |
| AU2005263550C1 (en) * | 2004-07-16 | 2013-01-17 | Lek Pharmaceuticals D.D. | Oxidative degradation products of atorvastatin calcium |
| CA2672554C (en) | 2004-07-20 | 2012-01-03 | Warner-Lambert Company Llc | Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl).beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
| TWI321132B (en) | 2004-09-28 | 2010-03-01 | Teva Pharma | Process for preparing forms of atorvastatin calcium substantially free of impurities |
| CA2582087A1 (en) * | 2004-10-18 | 2006-04-27 | Teva Pharmaceutical Industries Ltd. | Process for preparing amorphous atorvastatin hemi-calcium by dissolving the salt in an organic solvent which is a mixture of an alcohol and a ketone and/or an ester and removing the solvent |
| EP1807055A1 (de) | 2004-10-28 | 2007-07-18 | Warner-Lambert Company LLC | Verfahren zur herstellung von amorphem atorvastatin |
| DK1957452T3 (da) | 2005-11-21 | 2010-07-26 | Warner Lambert Co | Nye former af [R-(R*,R*)]-2-(4-fluorphenyl)-B,B-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-heptansyre- magnesium |
| EP1810667A1 (de) | 2006-01-20 | 2007-07-25 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmazeutische Zusammensetzung enthaltend amorphes Atorvastatin |
| KR100833439B1 (ko) * | 2007-01-02 | 2008-05-29 | 씨제이제일제당 (주) | 비결정형 아토르바스타틴 칼슘의 개선된 제조방법 |
| CZ201039A3 (cs) | 2010-01-19 | 2011-07-27 | Zentiva, K. S | Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme |
| HUP1000299A2 (hu) | 2010-06-08 | 2012-02-28 | Nanoform Cardiovascular Therapeutics Ltd | Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra |
| CN103288702B (zh) * | 2010-12-03 | 2015-09-16 | 上海科州药物研发有限公司 | 一种阿托伐他汀氨基酸盐的制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| ES2072468T3 (es) * | 1990-05-11 | 1995-07-16 | American Cyanamid Co | Nuevos arilpirroles n-acilados utiles como agentes insecticidas, acaricidas, nematicidas y molusquicidas. |
| HRP960312B1 (en) * | 1995-07-17 | 2001-10-31 | Warner Lambert Co | NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1) |
| BR9712072A (pt) * | 1996-09-20 | 1999-08-24 | Meiji Seika Kaisha | Subst-ncia cristalina de defditoren pivoxil e a produ-Æo da mesma |
-
1999
- 1999-10-18 HU HU9903634A patent/HU226640B1/hu not_active IP Right Cessation
-
2000
- 2000-10-17 EP EP00973115A patent/EP1235800B1/de not_active Expired - Lifetime
- 2000-10-17 CN CNB008144583A patent/CN1157374C/zh not_active Expired - Fee Related
- 2000-10-17 AT AT00973115T patent/ATE345327T1/de not_active IP Right Cessation
- 2000-10-17 RU RU2002113564/04A patent/RU2255932C2/ru not_active IP Right Cessation
- 2000-10-17 KR KR1020027004906A patent/KR100664353B1/ko not_active Expired - Fee Related
- 2000-10-17 SK SK519-2002A patent/SK286861B6/sk not_active IP Right Cessation
- 2000-10-17 WO PCT/HU2000/000106 patent/WO2001028999A1/en not_active Ceased
- 2000-10-17 AU AU11663/01A patent/AU1166301A/en not_active Abandoned
- 2000-10-17 CA CA002388018A patent/CA2388018C/en not_active Expired - Fee Related
- 2000-10-17 HR HR20020334A patent/HRP20020334B1/xx not_active IP Right Cessation
- 2000-10-17 CZ CZ20021256A patent/CZ300071B6/cs not_active IP Right Cessation
- 2000-10-17 DE DE60031882T patent/DE60031882T2/de not_active Expired - Fee Related
- 2000-10-17 UA UA2002054059A patent/UA72777C2/uk unknown
- 2000-10-17 PL PL00354604A patent/PL354604A1/xx not_active Application Discontinuation
- 2000-10-17 RS YUP-283/02A patent/RS50473B/sr unknown
- 2000-10-17 JP JP2001531799A patent/JP2003512354A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DE60031882T2 (de) | 2007-07-05 |
| HUP9903634D0 (en) | 1999-12-28 |
| KR20020063166A (ko) | 2002-08-01 |
| EP1235800B1 (de) | 2006-11-15 |
| CZ20021256A3 (cs) | 2002-08-14 |
| RS50473B (sr) | 2010-03-02 |
| KR100664353B1 (ko) | 2007-01-02 |
| HUP9903634A3 (en) | 2002-01-28 |
| WO2001028999A1 (en) | 2001-04-26 |
| EP1235800A1 (de) | 2002-09-04 |
| DE60031882D1 (de) | 2006-12-28 |
| HRP20020334A2 (en) | 2004-02-29 |
| CN1379760A (zh) | 2002-11-13 |
| HUP9903634A2 (hu) | 2001-12-28 |
| SK5192002A3 (en) | 2002-11-06 |
| CA2388018C (en) | 2008-04-08 |
| CN1157374C (zh) | 2004-07-14 |
| HU226640B1 (en) | 2009-05-28 |
| UA72777C2 (en) | 2005-04-15 |
| RU2255932C2 (ru) | 2005-07-10 |
| YU28302A (sh) | 2005-06-10 |
| SK286861B6 (sk) | 2009-06-05 |
| PL354604A1 (en) | 2004-01-26 |
| HK1050199A1 (en) | 2003-06-13 |
| CZ300071B6 (cs) | 2009-01-21 |
| HRP20020334B1 (hr) | 2007-12-31 |
| JP2003512354A (ja) | 2003-04-02 |
| AU1166301A (en) | 2001-04-30 |
| CA2388018A1 (en) | 2001-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE345327T1 (de) | Verfahren zur herstellung von amorphem atorvastatin kalzium | |
| ATE362759T1 (de) | Verfahren zur herstellung von amorphem atorvastatin kalzium | |
| DE69720579D1 (de) | Verfahren zur Depolymerisation von Polyestern | |
| ATE243672T1 (de) | Neue thyroid-rezeptorliganden und verfahren | |
| DE69706135D1 (de) | Verfahren zur Herstellung Simvastatin von Lovastatin oder Mevinolinsäure | |
| DE60008540D1 (de) | Aromatische ester von camptothecinen und verfahren zur behandlung von krebserkrankungen | |
| ATE216231T1 (de) | Verfahren zur herstellung von avermectin/zein- zusammensetzungen | |
| DE69405396D1 (de) | Verfahren zur synthese von nukleinsäuren auf einem festträger und verbindungen verwendbar als festträger in diesem verfahren | |
| ATE466015T1 (de) | Verfahren zur herstellung von phenserin und dessen analogon | |
| ATE521600T1 (de) | Verfahren zur herstellung von statinen | |
| ATE174601T1 (de) | Verfahren zur herstellung von bisnoraldehyden aus bisnoralkohol | |
| ATE187440T1 (de) | Verfahren zur herstellung von substituierten 3- aminobenzonitrilen | |
| DE69400343D1 (de) | Neues Verfahren zur Herstellung von 6alpha, 9alphadifluoro-Sterioden und Zwischenprodukte davon | |
| DE69426979D1 (de) | Verfahren zur herstellung von hiv-proteasehemmern | |
| DE69828166D1 (de) | Verfahren zur herstellung von mit radioaktivem iod markierten, neurorezeptor-wirksamen mitteln | |
| DE59609108D1 (de) | Verfahren zur herstellung eines kristallinen polymorphs von terazosin-hydrochlorid | |
| ATE146166T1 (de) | Verfahren zur herstellung von 2,2,-dimethyl-3- ((z)-2- (alkoxycarbonyl)ethenyl)cyclopropancarbonsäuree tern und zwischenprodukte | |
| Cerreti et al. | A novel synthesis of tricyclic-fused hydrindene–azetidinone compounds by sequential Mn (III)-promoted 4-exo-trig cyclization/radical aromatic substitution | |
| ATE376554T1 (de) | Verfahren zur herstellung von sterol- und stanol- estern | |
| DE69911502D1 (de) | Verfahren zur Behandlung von Kunststoffen auf mechanochemischem Weg | |
| ATE231485T1 (de) | Verfahren zur herstellung von arylmalonaten | |
| ATE540016T1 (de) | Verfahren zur herstellung von 21-4'- (nitrooxyalkyl)benzoatü corticosteroidderivaten und für deren synthese geeignete zwischenprodukte | |
| Lau et al. | Synthesis of penicillin N and isopenicillin N | |
| ATE301637T1 (de) | Verfahren zur herstellung von n-geschützten azetidin-2-carbonsäuren | |
| DE59604072D1 (de) | Verfahren zur Entsorgung von organischen Verbindungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |